Jang-Ho Cha

Jang-Ho Cha currently serves as Chief Scientific Officer at Latus Bio, a position held since December 2022. Previously, Jang-Ho Cha led Global Translational Medicine in Neuroscience at Novartis Institutes for BioMedical Research from December 2014 to December 2022. Jang-Ho Cha was actively involved with the Huntington's Disease Society of America as a member and Chair of the National Board of Trustees from 2007 to 2018. Prior to that, Jang-Ho Cha held various roles at Merck, including Head of Discovery Medicine, focusing on clinical experiments and drug development across therapeutic areas, as well as serving as Neuroscience Lead and Clinical Research lead. Jang-Ho Cha's early academic career included an Associate Professorship at Massachusetts General Hospital from 1996 to 2010, with a research focus on neurodegenerative diseases. Jang-Ho Cha's educational background includes MD and PhD degrees in Neuroscience from the University of Michigan, and an A.B. in Biology from Harvard University.